TB isn’t going away.
It has haunted humans for at least six millennia. Today it is still one of the deadliest infections on the planet. The numbers are blunt. One in four people on Earth carries the germ inside them right now, asymptomatic, silent. In 2024 alone, over ten million cases went active. 1.2 million deaths.
That makes TB the top killer from any single pathogen.
“Tuberculosis remains one of the world’s deadliest diseases” — but our tools feel old.
Doctors rely on long rounds of antibiotics. Patients struggle to finish them. Meanwhile, drug-resistant strains keep popping up. The World Health Organization says we need a change. Therapeutic vaccines could help. Shorten the treatment. Boost the immune system to clean house faster.
This is where the Johns Hopkins team jumps in.
They built a DNA vaccine. Not an injection. A nose spray.
The Biology Behind the Spray
It sounds simple, almost too simple. Inhale the dose. But the science underneath is precise.
Styliani Karanika led the study. She’s an assistant professor at Johns Hopkins School of Medicine and works with the Center for Tuberculosis Research. The team designed a fusion vaccine using two specific genes. relMtb and Mip3α.
Here is the logic. TB bacteria have a trick. The relMtb gene creates a protein that lets the bacteria hide. When things get tough — antibiotics, low oxygen, no food — the bug goes dormant. It survives. It waits. This is why treatment takes so long.
The researchers took that very gene and fused it with Mip3α.
The Mip3α acts as a beacon. It shouts out a signal. It draws immature dendritic cells to the party. These are the immune scouts. They pick up the TB proteins. They parade them in front of T cells. The T cells then coordinate the attack.
By using the enemy’s own survival gear against it, the vaccine wakes up the immune system. And by delivering it through the nose?
It hits the mucosa.
That is where the infection starts. The airways. The lungs.
“Intranasal delivery focuses vaccination on the site where infection occurs,” Karanika explains. “This helps generate localized immunity.”
The immune system learns to fight exactly where it counts. Systemically yes, but locally too.
Mice. Monkeys. And the Wait.
They tested it on mice first. The results looked promising. The infected mice cleared the bacteria faster than those on drugs alone. Lung inflammation dropped. Most importantly? No relapse.
They stopped the drugs. The mice stayed healthy.
When combined with a heavy-hitting drug cocktail (bedaquiline, pretomanid, and linezolid), the vaccine made those medicines work even better. This suggests a future path for treating resistant cases. Cases that are currently hard to treat. Or impossible to cure.
But mice aren’t humans.
So they moved to rhesus macaques.
The nose-delivered vaccine sparked measurable immune responses in the blood and airways. Similar patterns to what they saw in the mice. The response lasted. Six months out. The protection seemed durable.
Here is the catch though.
The monkey study checked immune activation only. They didn’t actually infect the primates with TB to see if they could stop it. We don’t know yet if this holds up under real attack in larger mammals.
Karanika is clear about it. This is a bridge. Not a crossing.
“These data give us a translational bridge between mouse efficacy and the work needed for human trials.”
We are not at clinical trials yet. More preclinical work is required. But the immunological promise is there.
Thinking Past Antibiotics
The researchers are betting on immunotherapy. Not just more antibiotics.
Standard drugs kill active bacteria. They miss the persisters. The dormant ones hiding out in tissues. The goal of this new strategy is to train the body to find them. To clean the slate completely.
DNA vaccines are stable. Easy to make. If this works in people — if the mouse and monkey data translates — the manufacturing logistics could be straightforward.
The list of names behind the study is long. Tianyin Wang. Addis Yilma. James Gordy. Many others from Johns Hopkins. Supported by grants from the National Institutes of Health and various foundations. Karanika, Gordy, and two others hold patents for the tech. They disclosed no conflicts of interest, but the potential is clear.
Will we soon be sniffing away a cure?
Probably not next month.
Science is slow. Human trials take years. Failures are common. But for a disease that has killed more than Hitler and the Black Plague combined…
Any new angle feels like progress.
